Trial Profile
In-Situ Cancer Vaccine: Phase I/IIb, Open-Label Study to Assess Safety of AllostimTM in Combination With Cryoablation in Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Immunovative Therapies
- 17 Jan 2020 Planned End Date changed from 31 Mar 2017 to 31 Mar 2014.
- 17 Jan 2020 Planned primary completion date changed from 30 Mar 2016 to 30 Mar 2014.
- 01 Apr 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.